



- Sub C17
B1
7. (New) A method comprising:
- diagnosing in a subject one or more HIV strain that is resistant to one or more chemotherapeutic agent; and
 - administering to the subject an effective viral reducing amount of a compound of the formula:



wherein x is: 2,5-OMe; *o*-F; *m*-F; *p*-F; or *o*-Cl.

8. (New) The method of claim 7, wherein the chemotherapeutic agent is Delavirdine, Nevirapine, Efavirenz, Trogidone, AZT, or MKC-442.


- Sub C27
9. (New) A method comprising:
- identifying in a subject a mutant form of HIV reverse transcriptase, the mutant form of HIV reverse transcriptase comprising an amino acid substitution at position 106 or 183; and
 - administering to the subject an effective mutant form of HIV reverse transcriptase reducing amount of a compound of the formula:



wherein x is: 2,5-OMe; *o*-F; *m*-F; *p*-F; or *o*-Cl.

10. (New) A method comprising:


- (a) identifying in a subject a mutant strain of HIV having a mutated HIV reverse transcriptase comprising one or more of the following amino acid substitutions: L100I, K103N, V106A, E138K, Y181C, or Y188H; and
- (b) administering to the subject an effective mutated HIV reverse transcriptase reducing amount of a compound of the formula:



wherein x is: 2,5-OMe; *o*-F; *m*-F; *p*-F; or *o*-Cl.

11. (New) A method comprising:

- (a) identifying in a subject one or more non-nucleoside inhibitor-resistant strain of HIV; and
- (b) administering to the subject an effective non-nucleoside inhibitor-resistant strain of HIV reducing amount of a compound of the formula:




wherein x is: 2,5-OMe; *o*-F; *m*-F; *p*-F; or *o*-Cl.

12. (New) A method comprising:


- (a) identifying in a subject a mutant HIV strain RT-MDR, A17, A17 variant, or a combination thereof; and

- (b) administering to the subject an effective mutant HIV strain RT-MDR, A17, A17 variant, or a combination thereof reducing amount of a compound of the formula:




wherein x is: 2,5-OMe; *o*-F; *m*-F; *p*-F; or *o*-Cl.


13. (New) The method of claim 7, wherein said compound is




or




14. (New) The method of claim 9, wherein said compound is




or



15. (New) The method of claim 10, wherein said compound is





or





*See Page 13
L10
supp = A-90
p15*

16. (New) The method of claim 11, wherein said compound is



or

17. (New) The method of claim 12, wherein said compound is



or